In in vivo models, we demonstrated that KRAS G12C inhibitors in combination with the FGFR inhibitor pemigatinib was most efficacious compared to single-agent treatment in the LU99 mesenchymal lung cancer model, which was correlated to increased inhibition of pERK in the combination group. Here, KRAS is linked to lung carcinoma.